OBJECTIVES: I. Determine the safety and efficacy of inhaled and subcutaneously administered heparin in the treatment of hereditary angioedema.

Condition	Treatment or Intervention
Angioedema	Drug: heparin

Further Study Details: 

Expected Total Enrollment:  24

PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, 3 way crossover study. All patients complete diary cards for the first month of the study in order to determine compliance in providing a daily record of symptoms and medication taken. All compliant patients receive subcutaneously injected heparin twice daily, inhaled heparin daily, or matched saline placebo in a random order. Each of the three drug administration periods lasts 2 months, for a total of 6 months of treatment. Patients who have a flare in disease activity that requires hospitalization are terminated from that drug administration period of the study. Patients are followed biweekly during the first month and again at the end of the second month for each of the three 2 month drug administration periods.

Ages Eligible for Study:  8 Years and above,  Genders Eligible for Study:  Both

Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

• Confirmed diagnosis of hereditary angioedema (HAE) based upon C4 antigenic level, positive family history, and C1 inhibitor (C1INH) antigenic level (Type I HAE) or functional level (Type II HAE)
• Functional C1 within normal levels if diagnosis of acquired C1INH is possible
• Negative family history will not exclude as long as patient meets all other criteria, has normal C1 level, and has no evidence of acquired C1INH deficiency
• History of symptoms of HAE including episodic swelling, abdominal pain, and/or respiratory difficulty
• Experiencing a minimum of 1-2 HAE episodes within 6 weeks

--Prior/Concurrent Therapy--

• Endocrine therapy: Anabolic steroids allowed as long as dose has not been changed in at least 30 days
• Other: No concurrent and at least 1 week since prior aspirin, nonsteroidal antiinflammatory agents, dipyridamole, Coumadin-like drugs, or any other medication having an effect on coagulation or platelets

--Patient Characteristics--

• Hematopoietic: No clinically significant history of hematologic disease
• Hepatic: No clinically significant history of hepatic disease
• Renal: No clinically significant history of renal disease
• Cardiovascular: No clinically significant history of cardiac disease or hypertension
• Pulmonary: No clinically significant history of pulmonary disease
• Other: No contraindication to the use of inhaled or subcutaneous heparin No drug allergy that would interfere with the study No clinically significant history of: Malignancy Diabetes mellitus Neurologic disease Immunologic disease Bleeding disorder Infirmity No history of drug abuse, alcoholism, psychosis, or other psychological/psychiatric disorder

Study chairs or principal investigators

John M. Weiler,  Study Chair,  University of Iowa   

Study ID Numbers:  199/13356; UI-9311397; UI-FDR001001
Record last reviewed:  April 1999
Last Updated:  October 13, 2004
Record first received:  February 24, 2000
ClinicalTrials.gov Identifier:  NCT00004694
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08